With capecitabine monotherapy, we observed notable reductions in proliferative CD8+ T cells, an immune inhibitory effect, and increases in both CD73+CD8+ T cells and CD226+ NK cells, which could have variable implications for anti-cancer immunity. Here, CD8A is linked to cancer.